{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:51:28Z","timestamp":1792036288213,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Western Norway Regional Health Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005029","name":"Helse Vest Regionalt Helsef\u00f8retak","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.msard.2021.103209","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T13:29:46Z","timestamp":1628515786000},"page":"103209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Incidence of cancer in multiple sclerosis before and after the treatment era\u2013 a registry- based cohort study"],"prefix":"10.1016","volume":"55","author":[{"given":"Nina","family":"Grytten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.","family":"Celius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Benjaminsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta T.","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Midgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Vatne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Aarseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Riise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103209_bib0001","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canep.2016.08.018","article-title":"Cancer co-occurrence patterns in Parkinson's disease and multiple sclerosis-Do they mirror immune system imbalances?","volume":"44","author":"Ajdacic-Gross","year":"2016","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"10.1016\/j.msard.2021.103209_bib0002","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103209_bib0003","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103209_bib0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1352458516646863","article-title":"Level of education and multiple sclerosis risk over a 50-year period: registry-based sibling study","volume":"23","author":"Bjornevik","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103209_bib0005","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/bmj.323.7319.968","article-title":"Mobility impairments and use of preventive services in women with multiple sclerosis: observational study","volume":"323","author":"Cheng","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103209_bib0006","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103209_bib0007","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/14728222.12.8.1009","article-title":"Downregulating sphingosine kinase-1 for cancer therapy","volume":"12","author":"Cuvillier","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.msard.2021.103209_bib0008","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fneur.2019.00337","article-title":"Cancer risk and multiple sclerosis: evidence from a large Italian cohort","volume":"10","author":"D'Amico","year":"2019","journal-title":"Front Neurol."},{"key":"10.1016\/j.msard.2021.103209_bib0009","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1634\/theoncologist.2007-0218","article-title":"FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia","volume":"13","author":"Demko","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.msard.2021.103209_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2021.103209_bib0011","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/1352458519877244","article-title":"Risk of cancer among multiple sclerosis patients, siblings, and population controls: a prospective cohort study","volume":"26","author":"Grytten","year":"2019","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2021.103209_bib0012","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41582-020-0329-3","article-title":"Socioeconomic status and multiple sclerosis outcome","volume":"16","author":"Hillert","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.103209_bib0013","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.0b013e3181c777b7","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"74","author":"Hofer","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103209_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.msard.2019.08.005","article-title":"Risk of cancer among Finnish multiple sclerosis patients","volume":"35","author":"Hongell","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103209_bib0015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/1535370214554881","article-title":"Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells","volume":"240","author":"Huang","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.msard.2021.103209_bib0016","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00415-012-6814-x","article-title":"Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway","volume":"260","author":"Kampman","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103209_bib0017","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia, Canada","volume":"135","author":"Kingwell","year":"2012","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.msard.2021.103209_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/135245859900500418","article-title":"The Danish multiple sclerosis registry: a 50-year follow-up","volume":"5","author":"Koch-Henriksen","year":"1999","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103209_bib0019","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","article-title":"Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness","volume":"45","author":"Larsen","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.msard.2021.103209_bib0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103209_bib0021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1748-717X-8-223","article-title":"New insights into the synergism of nucleoside analogs with radiotherapy","volume":"8","author":"Lee","year":"2013","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.msard.2021.103209_bib0022","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","article-title":"Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study","volume":"88","author":"Lunde","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2021.103209_bib0023","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3389\/fimmu.2019.02954","article-title":"Multiple sclerosis and cancer: the Ying-Yang effect of disease modifying therapies","volume":"10","author":"Melamed","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103209_bib0024","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103209_bib0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.msard.2021.103209_bib0026","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2018.12.014","article-title":"Multiple sclerosis and cancer incidence: a Danish nationwide cohort study","volume":"28","author":"Norgaard","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103209_bib0027","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0003-9993(97)90220-3","article-title":"Breast and cervical cancer screening among women with physical disabilities","volume":"78","author":"Nosek","year":"1997","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.msard.2021.103209_bib0028","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103209_bib0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.msard.2021.103209_bib0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103209_bib0031","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103209_bib0032","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/01.WNL.0000081305.66687.D2","article-title":"Smoking is a risk factor for multiple sclerosis","volume":"61","author":"Riise","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103209_bib0033","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ene.12267","article-title":"Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study","volume":"21","author":"Sun","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103209_bib0034","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103209_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acn3.37","article-title":"Month of birth and risk of multiple sclerosis: confounding and adjustments","volume":"1","author":"Torkildsen","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:37:53Z","timestamp":1786765073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":35,"alternative-id":["S2211034821004764"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103209","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of cancer in multiple sclerosis before and after the treatment era\u2013 a registry- based cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103209"}}